Related Experiment Videos

A rapid, quantitative bioassay based on the human immunodeficiency virus trans-activator

J M Hasler1, T F Weighous, T W Pitts

  • 1Division of Cancer and Infectious Diseases Research, Upjohn Company, Kalamazoo, MI 49001.

Summary

We developed a novel bioassay using a recombinant avian retrovirus (SNV-tat) to detect inhibitors of the human immunodeficiency virus trans-activator (TAT). This system enables rapid, quantitative, and safe screening for potential therapeutic compounds.

Related Concept Videos